We have described our efforts towards the successful bioisosteric
replacement of parent purine heterocyclic core with imidazo[
4,5-b]pyridine core and their cancer cell line activities. The
SAR study of these compounds was explored in detail and we
observed that the compound 6b displayed excellent potency and
good microsomal stability. Further studies are being conducted to
determine the mode of action of these compounds to provide an
insight into the design of future drugs.